biostudies-literatureUnknown22(2)Fugazzaro SRicerca Corrente Annual Program 2026Banca Popolare FoundationItalian Ministry of HealthFAS – Fondo Assistenza by Banco Popolare Group<h4>Background</h4>Cancer-related fatigue (CRF) reduces physical performance and quality of life (QoL). Some authors suggest including moderate-intensity physical exercise to manage CRF; however, the optimal timing to offer rehabilitation remains unclear. The primary aim is to investigate the feasibility of a pulmonary rehabilitation (PR) program, including physical exercise and educational sessions, for lung cancer patients undergoing cancer treatments; secondary objectives are to investigate its effect on CRF, physical performance, and QoL.<h4>Methods</h4>This randomized controlled trial enrolls 40 patients with stage II or III non-small-cell lung cancer undergoing chemotherapy, radiotherapy, or immunotherapy. Patients are randomly assigned to one of two groups: Group A (early-PR) beginsFuture oncology (London, England)147-156https://www.ebi.ac.uk/biostudies/studies/S-EPMC12802983biostudies-literatureFeasibility of an early versus delayed rehabilitation intervention in patients with lung cancer on cancer-related fatigue: a pilot RCT.PMC12802983Fugazzaro SBressi BCavuto SPecorari ACosti SFalco FDenti MCiammella PMainini CMessori MGalavotti MBZanelli FfalseFeasibility of an early versus delayed rehabilitation intervention in patients with lung cancer on cancer-related fatigue: a pilot RCT.<h4>Background</h4>Cancer-related fatigue (CRF) reduces physical performance and quality of life (QoL). Some authors suggest including moderate-intensity physical exercise to manage CRF; however, the optimal timing to offer rehabilitation remains unclear. The primary aim is to investigate the feasibility of a pulmonary rehabilitation (PR) program, including physical exercise and educational sessions, for lung cancer patients undergoing cancer treatments; secondary objectives are to investigate its effect on CRF, physical performance, and QoL.<h4>Methods</h4>This randomized controlled trial enrolls 40 patients with stage II or III non-small-cell lung cancer undergoing chemotherapy, radiotherapy, or immunotherapy. Patients are randomly assigned to one of two groups: Group A (early-PR) begins2026-01-01T00:00:00Z2026 Jan2026-06-06T14:55:52.049Z2026-06-01T03:08:02.695ZS-EPMC128029834149649210.1080/14796694.2025.2607632